Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5523931 | Best Practice & Research Clinical Haematology | 2016 | 11 Pages |
Abstract
Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paula Cramer, Barbara Eichhorst, Hans Christian Reinhardt, Michael Hallek,